A Phase II Trial of CI-958 in Recurrent Platinum-Sensitive Ovarian Carcinoma: A Gynecologic Oncology Group Study

By Hoffman M.A.   Blessing J.A.   Nunez E.R.  

Gynecologic Oncology, Vol. 81, Iss. 3, 2001-06 ,pp. : 433-435

Elsevier

Access to resources Recommend Favorite

Altretamine (Hexamethylmelamine) in Platinum-Resistant and Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Phase II Trial

By Markman M.   Blessing J.A.   Moore D.   Ball H.   Lentz S.S.  

Gynecologic Oncology, Vol. 69, Iss. 3, 1998-06 ,pp. : 226-229

Elsevier

Access to resources Recommend Favorite

Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

By Plaxe S.C.   Blessing J.A.   Bookman M.A.   Creasman W.T.  

Gynecologic Oncology, Vol. 84, Iss. 1, 2002-01 ,pp. : 32-35

Elsevier

Access to resources Recommend Favorite

Lack of Efficacy of 24-h Infusional Topotecan in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Trial

By Markman M.   Blessing J.A.   DeGeest K.   Morgan M.   Look K.Y.   Herzog T.J.   Rose P.G.  

Gynecologic Oncology, Vol. 75, Iss. 3, 1999-12 ,pp. : 444-446

Elsevier

Access to resources Recommend Favorite

Evaluation of Cisplatin and Cyclosporin A in Recurrent Platinum-Resistant Ovarian Cancer: A Phase II Study of the Gynecologic Oncology Group

By Manetta A.   Blessing J.A.   Hurteau J.A.  

Gynecologic Oncology, Vol. 68, Iss. 1, 1998-01 ,pp. : 45-46

Elsevier

Access to resources Recommend Favorite